ISR’s Hepatitis C Market Analysis Shows a Deep Pipeline, Uncovers Lack of Internet Search Visibility for Current Therapies

ISR’s Hepatitis C Market Analysis Shows a Deep Pipeline, Uncovers Lack of Internet Search Visibility for Current Therapies

<0> Industry Standard ResearchAndrew Schafer, 919-301-0106 </0>

(ISR) today announced the availability of their latest report, “,” providing a product and pipeline analysis of the Hepatitis C market, as well as a never before seen in-depth social media and search analysis detailing how individuals discuss and search for Hepatitis C information, where they go, and how their search progresses.

“Hepatitis C is the leading cause of liver cancer in the US and is believed to affect 170–200 million individuals worldwide,” explained Andrew Schafer, President of ISR. “Given the ups and downs in recent weeks, expectations for Hep C treatments remain high. This report gives both clinical development and brand managers information they need to meet these expectations.”

ISR’s report includes a social media and search analysis of Hepatitis C.

“The analysis of natural search engine ranking pages of commonly searched keyword phrases in the Hepatitis C search continuum uncovered a gap in what information users search for and what they expect to receive,” Schafer explained. “With few products available, this gap represents a tremendous opportunity for drug makers to assert themselves as information resource for Hepatitis C.”

ISR’s report also provides a disease overview; profile of current products and companies in the market; addressable market; and in-depth analysis of clinical trial activity, including 707 trials that are on-going or have been completed in the past two years to provide further understanding of trends in the Hepatitis C clinical development environment. The analysis includes the number of trials by phase, the average enrollment, the average length of the studies, the sponsor type, and the types of studies being run.

The report profiles the products and pipelines of 10 companies: Achillion, BMS, Boehringer Ingelheim, Genentech/Roche, Gilead Sciences, Idenix, Johnson & Johnson, Merck, Novartis, and Vertex.

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at , email , or follow ISR on Twitter @ISRreports.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.